Selecting highly affine and well-expressed TCRs for gene therapy of melanoma

Blood

Volumn 110, Issue 10, 2007, Pages 3564-3572

  Jorritsma, Annelies ^a   Gomez Eerland, Raquel ^a   Dokter, Maarten ^a   Van De Kasteele, Willeke ^a   Zoet, Yvonne M ^b   Doxiadis, Ilias I N ^b   Rufer, Nathalie ^c   Romero, Pedro ^c   Morgan, Richard A ^d   Schumacher, Ton N M ^a   Haanen, John B A G ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR;

ALLOIMMUNITY; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; GENE THERAPY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 36349004799     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-02-075010     Document Type: Article

References (50)

1. Romero P, Valmori D, Pittet MJ, et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev. 2002;188:81-96.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
3. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
4. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
5. Schumacher TNM. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2:512-519.
6. Coccoris M, de Witte MA, Schumacher TNM. Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther. 2005;5:583-593.
7. Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers antitumor reactivity. J Immunol. 1999;163:507-513.
8. Cooper LJN, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type I into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol. 2000;74:8207-8212.
9. Heemskerk MH, de Paus RA, Lurvink EGA, et al. Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc Natl Acad Sci U S A. 2001;98:6806-6811.
10. Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin Immunol. 2001;98:220-228.
11. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol. 2001;2:962-970.
12. Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TM. Immunotherapy through TCR gene transfer. Nat Immunol. 2001;2:957-961.
13. Kessels HW, Schepers K, van den Boom MD, Topham DJ, Schumacher TN. Generation of T cell help through a MHC class I-restricted TCR. J Immunol. 2006;177:976-982.
14. Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A. 2005;102:7934-7939.
15. De Witte MA, Coccoris M, Wolker MC, et al. Targeting self-antigens through allogeneic TCR gene transfer. Blood. 2006;108:870-877.
16. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients mediated by transfer of genetically engineered lymphocytes. Science. 2006;314:126-129.
17. Johnson LA, Heemskerk B, Powell DJ, et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J Immunol. 2006;177:6548-6559.
18. Romero P, Gervois N, Schneider P, et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol. 1997;159:2366-2374.
19. Debets R, Willemsen R, Bolhuis R. Adoptive transfer of T-cell immunity: gene transfer with MHC-restricted receptors. Trends Immunol. 2002;23:435-436.
20. + T cells. J Exp Med. 2003;198:569-580.
21. Calogero A, Hospers GA, Kruse KM, et al. Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer. Anticancer Res. 2000;20:1793-1799.
22. Zoet YM, Eijsink C, Kardol MJ, et al. The single antigen expressing lines (SALs) concept: an excellent tool for screening for HLA-specific antibodies. Hum Immunol. 2005;66:519-525.
23. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989;142:3714-3725.
24. Yssel H, de Vries JE, Koken M, van Blitterswijk W, Spits H. Serum-free medium for generation and propagation of functional human cytotoxic and helper T cell clones. J Immunol Methods. 1984;72:219-227.
25. Dietrich P-Y, Le Gal F-A, Dutoit V, et al. Prevalent role of TCR α-chain in the selction of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol. 2003;170:5103-5109.
26. Hughes MS, Yu YYL, Dudley ME, et al. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther. 2005;16:457-472.
27. Morgan RA, Dudley ME, Yu YYL, et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol. 2003;171:3287-3295.
28. Onishi M, Kinoshita S, Morikawa Y, et al. Applications of retrovirus-mediated expression cloning. Exp Hematol. 1996;24:324-329.
29. Toebes M, Coccoris M, Bins A, et al. Design and use of conditional MHC class I ligands. Nat Med. 2006;12:245-251.
30. Rodenko B. Generation of peptide-MHC class I complex through UV-mediated ligand exchange. Nat Protocols. 2006;1:1120-1132.
31. Overwijk WW, Tsung A, Irvine KR, et al. Gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998;188:277-286.
32. Heemskerk MHM, Hagedoorn RS, van der Hoorn MA, et al. Efficiency of T cell receptor expression in dual specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood. 2007;109:235-243.
33. Sommermeyer D, Neudorfer J, Weinhold M, et al. Designer T cells by T cell receptor replacement. Eur J Immunol. 2006;36:3052-3059.
34. Scholten KBJ, Kramer D, Kueter EWM, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human cells. Clin Immunol. 2006;119:135-145.
35. Sharp PM, Li WH. The codon adaptation index: a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. 1987;15:1281-1295.
36. Graf M, Deml L, Wagner R. Codon-optimized genes that enable increased heterologous expression in mammalian cells and elicit efficient immune responses in mice after vaccination of naked DNA. Methods Mol Med. 2004;94:197-210.
37. Maraninchi D, Blaise D, Rio B. Impact of T-cell depletion on outcome of allogeneic bone-marroow transplantation for standard-risk leukaemias. Lancet. 1987;330:175-178.
38. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173:7125-7130.
39. + T cells. Hum Gene Ther. 2004;15:648-658.
40. Weijtens MEM, Willemsen RA, Hart EH, Bolhuis RLH. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther. 1998;5:1195-1203.
41. Willemsen RA, Weijtens MEM, Ronteltap C, et al. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther. 2000;7:1369-77.
42. Engels B, Cam H, Schuler T, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther. 2003;14:1155-1168.
43. Bonini C, Ferrari G, Verzeletti S, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719-1724.
44. Verzeletti S, Bonini C, Marktel S, et al. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus leukemia: clinical follow-up and improved new vectors. Hum Gene Ther. 1998;9:2243-2251.
45. Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR-chains introduced into human T cells. Blood. 2007;109:2331-2338.
46. Rötzschke O, Falk K, Faath S, Rammensee H-G. On the nature of peptides involved in T cell allo-reactivity. J Exp Med. 1991;174:1059-1071.
47. + T-cell response. Nat Rev Immunol. 2004;4:595-602.
48. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Mounzer EA, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell Clones. Science. 1992;257:238-241.
49. + T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity. 2005;22:117-129.
50. Mendez MJ, Green LL, Corvalan JR, et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet. 1997;15:146-156.